Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 16/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076235 | 1.00 | GRAMD1A (0.49) | GRAMD1APDCD1CD274F10GCK | |
| SCHEMBL19713053 | 0.87 | PDCD1 (0.49) | GRAMD1APDCD1CD274F10GCK | |
| SCHEMBL30076348 | 0.87 | PDCD1 (0.49) | GRAMD1APDCD1CD274F10GCK | |
| SCHEMBL975339 | 0.84 | GRAMD1A (0.53) | GRAMD1AF10GCK | |
| SCHEMBL31354371 | 0.84 | GRAMD1A (0.45) | GRAMD1APDCD1CD274F10GCK | |
| SCHEMBL20296267 | 0.83 | F10 (0.61) | PDCD1CD274F10F2F9 | |
| SCHEMBL25059904 | 0.82 | GRAMD1A (0.47) | GRAMD1AF10GCK | |
| SCHEMBL22966870 | 0.82 | GRAMD1A (0.49) | GRAMD1APDCD1CD274F10GCK | |
| SCHEMBL20293591 | 0.81 | PDCD1 (0.54) | PDCD1CD274 | |
| SCHEMBL29812811 | 0.81 | PDCD1 (0.54) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3472167-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-10-14 | — | — | US | disclosed |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-10-14 | — | — | US | disclosed |
| EP-3472167-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190040082-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20190040082-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | disclosed |
| WO-2017222976-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GRAMD1A 4670/4885PDCD1 157/4885CD274 88/4885 |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | GRAMD1A 4670/4885PDCD1 157/4885CD274 88/4885 |
| US-20190040082-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GRAMD1A 4670/4885PDCD1 157/4885CD274 88/4885 |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GRAMD1A 4670/4885PDCD1 157/4885CD274 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.